PolarityTE Responds To Citron Research Report, Strongly Disputes Any Claim That Current Directors Or Officers Have Sold Shares Of Co.'s Stock In Last 12 Months; Says Lack Of Issued Patents Should Not Deprive Patients Of Real Potential Benefits
Benzinga Newsdesk